- Nā lāʻau lapaʻau
- Nā Hōʻike Manaʻo
- ʻO ka Neuroblastoma
- Puʻupuʻu paʻa
- Nā Hōʻike Manaʻo
- TILS
- NK Cell Therapy
- ʻO ka Myasthenia Gravis (MG)
- ʻO ka maʻi leukemia lymphoblastic koʻikoʻi (B-ALL)
- ʻO ka Lupus Erythematosus Pūnaehana (SLE)
- ʻO ka maʻi leukemia lymphoblastic koʻikoʻi (T-ALL)
- ʻO ka Lymphoma Non-Hodgkin (NHL)
- ʻO ka Myeloma Nui (MM)
- ʻO ka Lymphom cell B nui e hoʻolaha ʻia
- ʻO ka maʻi leukemia lymphocytic B
- Myeloma
CAR-T no ka maʻi Leukemia Lymphoblastic B-cell ʻoʻoleʻa (B-ALL)
ʻIke laulā
ʻO B-ALL (Acute B-cell Lymphoblastic Leukemia) kahi ʻano leukemia ikaika, e hoʻopilikia nui ana i nā keiki a me nā ʻōpio. ʻOiai ka holomua ʻana o ka chemotherapy kuʻuna, nui nā maʻi e ʻike i ka relapse a i ʻole ke kūʻē ʻana i ka lāʻau. ʻO ka CAR-T (Chimeric Antigen Receptor T-cell) therapy ke ʻano o kahi immunotherapy groundbreaking i hōʻike i ka holomua kupaianaha i ka mālama ʻana i ka relapsed a refractory paha B-ALL, e hāʻawi ana i ka manaʻolana no nā maʻi i loaʻa mua nā koho lapaʻau palena.
He aha ka lāʻau lapaʻau CAR-T?
ʻO ka lāʻau lapaʻau CAR-T kahi lāʻau lapaʻau holomua a pilikino e pili ana i ka hoʻololi ʻana i nā T-cell ponoʻī o ka mea maʻi e ʻike a hoʻouka i nā cell cancer. No B-ALL, ua hana ʻia nā CAR-T cell e kuhikuhi i ka antigen CD19, kahi protein i loaʻa pinepine ma ka ʻili o nā cell leukemia B-cell. Ke hoʻokomo hou ʻia i loko o ke kino o ka mea maʻi, ʻimi kēia mau T-cell i hana ʻia a luku i nā cell leukemia, e alakaʻi ana paha i ke kala ʻana no ka manawa lōʻihi.
Nā Pōmaikaʻi Koʻikoʻi o ka CAR-T Therapy no B-ALL
- Ka Pono KiʻekiʻeUa hōʻike ʻo CAR-T therapy i ka holomua kupaianaha i ka mālama ʻana i ka B-ALL i hoʻihoʻi ʻia a paʻakikī paha, e hāʻawi ana i kahi kiʻekiʻe o ke kala ʻana i nā poʻe maʻi i pane ʻole i nā lāʻau lapaʻau kuʻuna.
- Hana i Hoʻolālā ʻiaMa ka nānā ʻana i ka antigen CD19, kuhikuhi pono ka lāʻau lapaʻau CAR-T a luku i nā pūnaewele B-ALL, e hoʻemi ana i ka hōʻino ʻana i nā ʻiʻo olakino.
- Lapaʻau pilikinoʻOiai ua loaʻa nā pūnaewele CAR-T mai ka ʻōnaehana pale ponoʻī o ka mea maʻi, ua pilikino loa ka lāʻau lapaʻau, e hoʻonui ana i kona pono a me ka hoʻemi ʻana i ka pilikia o ka hōʻole ʻia.
- Kala ʻana PaʻaI nā hihia he nui, ua alakaʻi ka lāʻau lapaʻau CAR-T i ke kala mau loa, e hāʻawi ana i nā mea maʻi i ka hiki ke ola lōʻihi me ka emi ʻana o nā relapses.
Kaʻina Hana Lapaʻau
- ʻOhiʻohi o nā pūnaewele TʻO ka hana mua e pili ana i ka hōʻiliʻili ʻana i nā pūnaewele T mai ke koko o ka mea maʻi ma o ke kaʻina hana i kapa ʻia ʻo leukapheresis.
- ʻEnekinia ʻana i nā pūnaewele THoʻololi ʻia nā pūnaewele T i hōʻiliʻili ʻia ma ke ʻano genetic i loko o ka hale hana e hōʻike i kahi mea hoʻokipa antigen chimeric (CAR) kūikawā i CD19, e hoʻonui ana i ko lākou hiki ke kuhikuhi i nā pūnaewele B-ALL.
- Hoʻokomo ʻia ʻana o nā pūnaewele CAR-TMa hope o kahi manawa pōkole o ka hoʻonui ʻana o ke kelepona, ua hoʻihoʻi ʻia nā pūnaewele CAR-T i hana ʻia i loko o ke kino o ka mea maʻi ma o kahi hoʻokomo intravenous (IV).
- Ka Nānā ʻana a me ka Hoʻōla ʻanaMa hope o ka hoʻokomo ʻana, nānā pono ʻia nā mea maʻi no nā hopena ʻaoʻao e like me ka cytokine release syndrome (CRS) a me ka neurotoxicity. Hiki ke hoʻokele ʻia kēia mau hopena, a hoʻōla ka hapa nui o nā mea maʻi me nā hana kūpono.
No ke aha e koho ai i ka CAR-T Therapy a BIOOCUS no B-ALL?
- ʻenehana hou loaHoʻohana ʻo BIOOCUS i ka ʻenehana holomua loa e hōʻoia i ka hana ʻana o nā cell CAR-T kūpono loa a me nā hopena maʻi.
- Pūʻulu Lapaʻau AkamaiUa hoʻolaʻa ʻia kā mākou hui o nā loea i ka hematology a me ka immunotherapy i ka hāʻawi ʻana i ka mālama pilikino a me ka hoʻonui ʻana i ka holomua o kēlā me kēia lāʻau lapaʻau.
- ʻIke HonuaHāʻawi mākou i ka lāʻau lapaʻau CAR-T i nā poʻe maʻi mai ka honua holoʻokoʻa, me kahi moʻolelo o nā lāʻau lapaʻau holomua a me ke kala ʻana no ka manawa lōʻihi no nā poʻe maʻi B-ALL.
- Mālama pihaMai ke kūkākūkā mua ʻana a hiki i ka nānā ʻana ma hope, hāʻawi ʻo BIOOCUS i ka mālama piha piha, e hōʻoiaʻiʻo ana e loaʻa i nā mea maʻi ka lāʻau maikaʻi loa i kēlā me kēia pae.
Nā Hōʻike Lapaʻau a me nā Kūlana Holomua
Ua hōʻike ʻia nā hoʻokolohua lapaʻau hou a me nā ʻikepili o ke ao maoli e hāʻawi ana ka lāʻau CAR-T no B-ALL i nā hopena kūikawā, ʻoiai no nā poʻe maʻi i hoʻi hou i ka maʻi a i ʻole kūʻē i nā lāʻau kuʻuna. Ua hōʻike mau ka lāʻau lapaʻau i nā helu kala kiʻekiʻe, me ka nui o nā poʻe maʻi e loaʻa ana ke kala piha a me ka mālama ʻana i ke ola lōʻihi.
Ma BIOOCUS, ua mālama pono mākou i nā maʻi he nui me B-ALL me ka hoʻohana ʻana i ka lāʻau lapaʻau CAR-T, a ua maikaʻi loa nā hopena. No ka hoʻomaopopo hohonu ʻana i nā moʻolelo holomua a me nā hopena maoli, e ʻoluʻolu e nānā i nā haʻawina hihia maʻi ma lalo nei:
- Ka Moʻolelo o ka Mea Maʻi: B-ALL Kiʻekiʻe-Pilikia, Hoʻoili ʻana o ka Iwi ʻŌpū i 9 Mahina—ʻElua Makahiki Ma Hope, He Hoʻomaka Ola Kino
- Mai ka hāʻule mua ʻana o ka Graft a hiki i ka ho'ōla piha ʻana: Ka huakaʻi a ka mea maʻi me ka Advanced Transplant a Lu Daopei
- ʻIke Huahana a me nā Haʻawina Hihia no ka Leukemia Lymphoblastic Akute (B-ALL)
Hōʻike kēia mau hihia i ka hiki ke hoʻololi i ka lāʻau lapaʻau CAR-T no nā poʻe maʻi B-ALL, e hōʻike ana ʻaʻole wale i ka pono o ka lāʻau lapaʻau akā i kona hiki ke hāʻawi i nā mea maʻi i kahi manawa lua i ke ola.
ʻIkepili Lapaʻau
Nā hōʻailona no CD19+20CAR-T:Nā maʻi me ka lymphoma B-cell non Hodgkin
| Ka uku CR hoʻokahi mahina | Ka uku PR hoʻokahi mahina | Hoʻokahi mahina OR uku | CRS≥3 | CRES≥3 |
| 71.95%(59/82) | 25.6(21/82) | 97.55(80/82) | 12.19%(10/82) | 0 |
Nā hōʻailona no CD19+22CAR-T:Ka mālama ʻana i nā maʻi leukemia B-lymphocytic acute i hoʻihoʻi ʻia mai ka CD19 a me ka refractory
| Ka uku CR hoʻokahi mahina | Ka uku PR hoʻokahi mahina | Hoʻokahi mahina OR uku | CRS≥3 | CRES≥3 |
| 92.1%(35/38) | 7.9%(3/38) | 100%(38/38) | 15.79%(6/38) | 0 |
Nā hōʻailona no BCMACAR-T:Ka mālama ʻana i ka myeloma maha relapsed a me ka refractory
| Ka uku CR hoʻokahi mahina | Ka uku PR hoʻokahi mahina | Hoʻokahi mahina OR uku | CRS≥3 | CRES≥3 |
| 72.41%(21/29) | 27.59%(8/29) | 100%(29/29) | 6.9%(2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.



